NASDAQ$SVRA
Savara Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Savara reported an increased net loss in Q4 2024, driven by higher R&D and G&A expenses as it advanced the MOLBREEVI program.
In Q4 2024, Savara posted a net loss of $29.04 million or $(0.13) per share, primarily due to increased investment in research and development and commercial preparation for MOLBREEVI. The company ended the quarter with strong liquidity, holding $196.33 million in cash and short-term investments.
- Net loss widened to $29.04 million from $16.1 million in Q4 2023.
- EPS came in at $(0.13), down from $(0.09) a year earlier.
- R&D expenses nearly doubled year-over-year to $23.3 million.
- Cash and short-term investments totaled $196.33 million at quarter-end.
Headline financials
Revenue & EPS history
Savara · Revenue · Quarterly
$0
Forward guidance
Savara expects to maintain a strong financial position with a projected cash runway into 2Q 2027 and is focused on advancing regulatory and commercial activities for MOLBREEVI.
Tailwinds
- Completed BLA submission for MOLBREEVI to the FDA.
- Requested Priority Review, with potential approval by end of 2025.
- Commercial launch preparations underway for early 2026.
- Orphan Drug and Breakthrough Therapy Designations obtained.
- Strong cash position with $196M on hand excluding debt financing.
Headwinds
- Increased net loss due to higher R&D and G&A expenses.
- No product revenue reported in Q4 2024.
- Operational losses widened year-over-year.
- Pending regulatory approval adds uncertainty to timelines.
- Continued reliance on capital markets and debt for funding.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2024
-1.1%
Avg return
Earnings day
+0.8%
Avg return
5 days after
+7.5%
Avg return
30 days after
35%
13 / 37 earnings
Positive
+12.5%
Q3 2018
Best reaction
-20.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | — | — | — | |
| Q1 2026 | -0.8% | -1.8% | +2.5% | |
| Q4 2025 | -0.8% | +3.4% | -3.0% | |
| Q3 2025 | -4.9% | -3.0% | +59.8% | |
| Q2 2025 | +5.5% | +18.2% | +38.0% | |
| Q1 2025 | +9.9% | +23.7% | +13.9% | |
| Q4 2024 | +4.7% | +8.3% | +14.4% | |
| Q3 2024 | -20.1% | -26.8% | -17.7% | |
| Q2 2024 | +4.0% | +9.3% | +8.5% | |
| Q1 2024 | -6.6% | -3.6% | -20.6% | |
| Q4 2023 | -2.2% | -9.2% | -11.8% | |
| Q3 2023 | -6.2% | -0.5% | +12.4% | |
| Q2 2023 | +4.3% | +3.8% | -0.8% | |
| Q1 2023 | +8.5% | +31.7% | +60.8% | |
| Q4 2022 | -3.9% | -15.8% | -7.4% | |
| Q3 2022 | +5.4% | +18.0% | +42.3% | |
| Q2 2022 | +3.0% | -0.6% | -10.8% | |
| Q1 2022 | +3.6% | +20.0% | +28.2% | |
| Q4 2021 | +5.6% | +3.2% | -4.8% | |
| Q3 2021 | -1.7% | -3.4% | -10.3% | |
| Q2 2021 | -3.3% | -4.1% | +17.9% | |
| Q1 2021 | +1.3% | +5.2% | +18.8% | |
| Q4 2020 | -13.6% | -3.8% | +6.0% | |
| Q3 2020 | -3.7% | +3.7% | +32.1% | |
| Q2 2020 | +0.0% | -8.0% | -41.0% | |
| Q1 2020 | -2.5% | +2.1% | +0.8% | |
| Q4 2019 | -2.5% | +0.4% | -10.2% | |
| Q3 2019 | -7.6% | -15.8% | +22.1% | |
| Q2 2019 | -6.5% | -3.7% | -1.6% | |
| Q1 2019 | +2.0% | +0.5% | -7.8% | |
| Q4 2018 | -4.2% | -2.7% | +11.5% | |
| Q3 2018 | +12.5% | +2.9% | -20.3% | |
| Q2 2018 | -2.6% | -7.6% | -2.0% | |
| Q1 2018 | -5.8% | -4.7% | +14.9% | |
| Q4 2017 | -4.5% | -1.0% | -12.4% | |
| Q3 2017 | -4.3% | +4.4% | +49.3% | |
| Q2 2017 | -3.7% | -4.2% | +13.3% | |
| Q1 2017 | -0.5% | -7.4% | -7.9% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro